STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-06-14
Here’s whether Denali Therapeutics Inc. Common Stock (DNLI) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.34% over 10 days); strong 1-year return of +45.1%; 3-month momentum positive (+5.3%). Currently 8.9% off its 52-week high. Score: +6/7.
DNLI is in a confirmed uptrend, trading above both its 50-day ($19.76) and 200-day ($18.23) moving averages. An RSI of 68.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +45.1% compares to +22.9% for SPY (beat the market by 22.3%).
$10,000 invested 1 year ago→ $14,513 today
vs. S&P 500 (SPY) — same period beat market by 22.3%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($18.23)
✓Above 50-day MA ($19.76)
✓RSI(14) neutral zone (30–70) — currently 68.9
✓Positive return (+45.1%)
✓Within 10% of period high (−8.9%)
Period Range $21.66
$12.58$23.77
RSI (14) 68.9
0 · OversoldOverbought · 100
Key Metrics
Price$21.66
Period Return+45.1%
Period High$23.77
Period Low$12.58
Drawdown−8.9%
MA-50$19.76
MA-200$18.23
RSI (14)68.9
Avg Volume (30d)1.9M
vs. SPYbeat by 22.3%
Return Rank#362 of 1246
Trend Signals
Price is above the 200-day moving average ($18.23)